Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune‐related hepatitis in non–small cell lung cancer patients with chronic hepatitis B

Documenti analoghi

• Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience
  di: Sehhoon Park, et al.
  Pubblicazione: (2026)
• Antiviral prophylaxis for hepatitis B virus reactivation in T‐cell lymphoma patients with resolved hepatitis B virus infection
  di: Liyun Qiu, et al.
  Pubblicazione: (2025)
• Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
  di: Matthew J. Townsend, et al.
  Pubblicazione: (2024)
• Reply to: Comments on “Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients”
  di: Mi Na Kim, et al.
  Pubblicazione: (2024)
• Clinical implications of hepatitis B virus core antigen‐mediated immunopathologic T cell responses in chronic hepatitis B
  di: Li‐Tzu Wang, et al.
  Pubblicazione: (2024)